June 2019 Appendix 4C - Quarterly
Filed with ASX · · 9 pages · English
MELBOURNE Australia, 24 July 2019: Clinical-stage targeted oncology company Prescient Therapeutics Limited (ASX: PTX) (“Prescient”) today reported its June 2019 quarter results and operating highlights. Financial update The business ended the quarter with cash reserves of A$9.64 million. This included proceeds from the second tranche of our placement and non-renounceable rights issue which closed
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- PTX Initiates Phase 1b Clinical Trial for PTX-100
- Change to Exercise Price of Options
- Canadian Patent Granted for PTX-200
- Entitlement Offer Results and Shortfall Notification
- March 2019 Appendix 4C - Quarterly
Later from Prescient Therapeutics
- Appendix 4E and 2019 Annual Report
- September 2019 Appendix 4C - Quarterly
- Prescient Ausbiotech Ras Presentation
- Receipt of R&D Tax Rebate
- 1st patient dosed in trial for first in class drug PTX-100
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics